Mutation rates of IDH1 and IDH2 were higher in AML, NOS and AML-MRC-MLD than in AML-MRC-C (IDH1: 10%, 13%, and 7% and IDH2: 23%, 17%, and 11%, respectively, Supplementary Fig. 3). This evidence concerns the gene IDH1 and acute myeloid leukemia.